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Background: Chemotherapy-induced anaemia is a common and significant complication of chemotherapy
treatment. Blood transfusion and administration of Erythropoiesis-Stimulating Agents (ESAs) either alone or in
combination with iron are the most widely used therapeutic options. In Greece, ESAs are among the top ten
therapeutic groups with the highest pharmaceutical expenditure, since they are fully reimbursed by social security
funds. The objective of the study is to determine potential cost savings related with the use of biosimilar over
originator ESAs for the management of the newly diagnosed chemotherapy-induced anemic patients.
Methods: A budget impact analysis has been carried through the elaboration of national epidemiological, clinical
and economic data. Epidemiological data derived from WHO (GLOBOCAN) and the European Cancer Anaemia
Survey. Clinical data reflect oncology patients’ disease management. ESAs consumption was based on data from
the biggest social security fund (IKA). The administration of ESAs under different dosing schemes and time periods
has been estimated by separating them in originators and biosimilars as well as by classifying anaemic patients in
responders and non-responders. Cost analysis is based on newly diagnosed patients’ alternative treatment
scenarios. Treatment costs and prices are used in 2012 values. The Social Security Funds’s perspective was
undertaken.
Results: Based on the annual incidence rates, 2.551 newly diagnosed chemotherapy-induced anemic patients are
expected to be treated with ESAs. Average cost of treatment on originators ESAs for responders is €2.887 for the
15-week ESAs treatment and €5.019 for non-responders, while on biosimilars €2.623 and €4.009 respectively.
Treatment cost on biosimilars is 10.1% lower than originators for responders and 25.2% for non-responders. Budget
impact estimates show that treating anemic patients with originator ESAs was estimated at €10.084.800 compared
to €8.460.119 when biosimilar ESAs were used, leading to an overall 19,20% cost reduction favoring biosimilars.
Conclusion: In Greece, the treatment on biosimilar ESAs seems to be a cost saving option over originators for the
newly diagnosed chemotherapy-induced anemic patients, since it corresponds to 5% of the annual overall
consumption and expands patients’ access to ESAs treatment. Health care decision making should rely on evidence
based treatments in order to achieve social funds’ sustainability in an era of economic recession.
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The European Cancer Anaemia Survey (ECAS) has re-
vealed a high prevalence and incidence rates of anaemia
in cancer patients in Europe since it examined disease’s
evolution, severity and management in a large and repre-
sentative population sample of European cancer patients
[1,2]. Chemotherapy-induced anaemia is a common and
significant complication of chemotherapy treatment, with
an incidence rate of 62.7% [1]. Additionally, anaemia has
been reported in 19.5% of patients in the first chemother-
apy cycle rising up to 46.7% of patients in the fourth and
fifth chemotherapy cycle [1].
Therapeutic options provide supportive care through
transfusion with packed red blood cells or administration
of Erythropoiesis-Stimulating Agents (ESAs), with or
without iron supplementation [3,4]. Transfusions are
recommended to correct very low (<9 g/dl) Hb levels, but
not for Hb values above that level [4-6]. Additionally, they
are related with risk issues such as infections, disease
transmissions and blood availability reduction [4,7-10].
Supplementing ESA therapy with intravenous iron has
been shown to increase hemoglobin response rates com-
pared with ESA alone, to levels similar to those observed
for transfusions [11-13]. This evidence is also supported
by Aapro et al., 2012 [14] review which showed higher
efficacy of intravenous iron over oral or no iron in redu-
cing blood transfusions, increasing haemoglobin levels,
and improving quality of life in ESAs-treated anaemic
cancer patients. Additionally, by adding intravenous iron
to ESA therapy the cost of ESA treatment across the
therapeutic class is reduced [15].
ESAs are genetically engineered forms of erythropoietin.
Based on their approved indications, by the European
Medicines Agency (EMA), they are used for the treatment
of symptomatic anaemia associated with chronic renal
failure as well as the treatment of adult cancer symptom-
atic anaemia patients with non-myeloid malignancies
receiving chemotherapy. It should be mentioned that
there is a controversy in the international literature
concerning safety and effectiveness issues related with
the use of ESAs [16,17].
There is suggestive evidence that the use of ESAs in
patients with chemotherapy-induced anaemia may im-
prove disease-specific measures of quality of life and
decreases the use of blood transfusions [18-25].
The first biosimilars of ESAs were developed after the
patent expiry of the originators. The term biosimilar
designates a second-entry version of biological medicinal
products whose complex molecular structure is more
challenging and requires greater resources than trad-
itional generics [26-31]. The approval process that has
been applied for generics is unsuitable for biosimilars
and specific provisions for these products were devel-
oped. Their authorization is granted on the basis ofquality, safety and efficacy data [32]. There is a real
choice available to physicians when selecting different
ESAs products, since it appears to have no significant dif-
ference in the effectiveness and safety of different agents
in managing chemotherapy-induced anaemia [5,33].
ESAs are among the top ten therapeutic groups with
the highest pharmaceutical expenditure ranging from
26,4% in 2008 to 22,7% in 2010, as reported by IKA, the
biggest social security fund in Greece until 2011 [34].
The market share (MS) of originator epoetins was 99%
in 2008 corresponding to €41,4 million. In 2009 ESAs
expenditure reached €43 million, with 94% and 6% MS
for original and biosimilar ESAs respectively, whilst in
2010 an inverse tendency appeared presenting an in-
crease of MS of biosimilars to 19%. The same year ESAs
expenditure was almost halved (€19 million) since cost-
containment measures were implemented such as flat
price cuts and stricter control of prescriptions [35].
Therefore, although ESAs are widely used treatments,
they remain a costly option since they are fully reim-
bursed (100%) by all social security funds without any
patient co-payment. Under the current economic reces-
sion that Greece is facing, numerous cost containment
measures have been implemented in all fiscal sectors. In
the health care sector, the majority of the measures
performed targeted to pharmaceutical expenditure [35].
The objective of this paper is to elaborate epidemio-
logical, clinical and economic data on ESAs consumption
in Greece, in order to determine potential cost savings by
using biosimilar over originator ESAs under different dos-
ing schemes for the management of the newly diagnosed
chemotherapy-induced anemic patients.
Methods
A budget impact analysis has been carried out based on
national epidemiological, clinical and economic data.
Epidemiological data concerning the incidence of cancer
in Greece derived from IARC-WHO (GLOBOCAN)
2008 [36]. Anaemia treatments separated in ESAs (either
alone or in combination with iron and/or transfusion),
transfusion (alone or with iron) and iron alone were
based on the European Cancer Anaemia Survey (ECAS)
[1]. Incidence of cancer–associated anaemia for the
Greek oncologic patients was performed by type of can-
cer: breast, lung, GI/colocteral, head/neck, gynecological,
lymphoma/myeloma, leukemia, urogenital and a cat-
egory containing the remaining cancer types.
The classification of ESAs per Hb level and strength
has been estimated by separating them in originators
(darbepoetin α, epoetin α and epoetin β) and biosimilars
(epoetin α and epoetin ζ) for a two month period as well
as for a time period of six chemotherapy cycles on ESA
treatment, aligned with routine chemotherapy duration.
Approved ESAs classification, per strength and price
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presented in Table 1.
The recommended initial doses of ESAs, based on
their approved by EMA Summary of Product Character-
istics (SPC) are 30.000 IU/week (or 3 × 10.000 IU/week)
for epoetin α, epoetin β and epoetin ζ and 150 mcg/week
for darbepoetin α. Alternate approved doses for epoetin
α/epoetin ζ and darbepoetin α are 40.000 IU/week and
500m cg/3 weeks respectively.
If Hb has not increased by at least 1 g/dl after 4-week
treatment with epoetin α, epoetin β and epoetin ζ, the
dose may be escalated to 200% of the initial dose. Based
on the US National Comprehensive Cancer Network,
(NCCN) clinical practice guidelines in Oncology for the
treatment of cancer and chemotherapy-induced anaemia
[37], the dose of darbepoetin α could be increased up to
4.5 μg/kg once a week corresponding to 300 μcg/week
in case of no response at 6-week treatment with the ini-
tial darbepoetin dose. In order to be able to compare
darbepoetin with the rest epoetins, at various stages ofTable 1 ESAs classification per strength (IU/mcg) and





















Brand Strength Active substance Average hospital
price/syringe (€)*
ABSEAMED 10.000 IU 50.26




BINOCRIT 20.000 IU Epoetin α 94.37
30.000 IU 141.55
40.000 IU 188.73
10.000 IU Epoetin ζ 54.51
RETACRIT 40.000 IU 255.54
*Hospital Prices 2012.the chemotherapy-induced anaemia treatment, the escal-
ation of dosage scheme to 200% was performed in
4 weeks interval instead of 6 weeks (Table 2).
In case the Hb has not increased by at least 1 g/dl
after 4 consecutive weeks (8 weeks in total) with the es-
calated ESAs dose, the treatment with epoetin α, epoetin
β and epoetin ζ should be discontinued. Concerning
darbepoetin α, in case of patient’s non-response (fatigue,
haemoglobin response) after nine weeks of treatment,
further therapy may not be effective, according to the
SPC recommendations.
Based on the national clinical guidelines [38] as
well as the European Society for Medical Oncology
(ESMO) guidelines [39], chemotherapy duration varies
from 4–6 cycles depending on the type of cancer. In
the current analysis six cycles of chemotherapy were
used at three-week intervals. A chemotherapy cycle
was defined as the three-week period with the chemother-
apy being administered at the first week of each cycle. The
6-cycle chemotherapy corresponds to 18 weeks. The initi-
ation of ESAs treatment was assumed to take place at the
beginning of the second chemotherapy cycle i.e. at week 4
and continued until the end of the 6th cycle of chemother-
apy (end of week 18), for a total of 15 weeks [1,5].
Two different ESAs escalating dosing schemes
were used (Table 2) leading to the classification of
chemotherapy-induced anaemic patients in responders
and non-responders with a 50% response rate per group.
Responders were administered the recommended initial
doses of ESAs for the total of 15 weeks, while non re-
sponders’ dosing scheme was escalated to 200% of the
initial dose in the beginning of the week 9 until the end
of 15th week.
Each ESA can be used in more than one fixed dosing
scenario (Table 2). In order to enable a clinically relevant
comparison, the cost of all possible fixed dosing schemes
were taken into account and average cost estimates per
month of originator and biosimilar ESAs were used.
Cost analysis among originator and biosimilar ESAs
was based on a two-month treatment period per patient.
In the budget impact analysis the cost estimates for the
two-month period treatment were extrapolated to a six-
cycle chemotherapy framework based on the incidence
rates, Hb level, distributed in responders and non re-
sponders. Hospital prices were averaged using 2012
values. The Social Security Funds’s perspective was
undertaken and for data elaboration Microsoft Excel
version 7 was used.
Results
Newly diagnosed cancer patients in Greece are estimated at
37.089 out of which 14.660 are expected to be treated for
anaemia (Table 3). From those 2.551 (17.4%) chemotherapy-
induced anaemic patients will be treated with ESAs.
Table 2 Dosage Scheme of ESAs for “Responders” and “Non-Responders” Anaemic Patients for a two-month period
Active
substance
Responders (Hb increase ≥ 1 g/dl) Non responders (Hb increase < 1 g/dl)
First month treatment Second month treatment First month treatment Second month treatment








3 × 10.000 IU/week
or 30.000 IU/week
3 × 10.000 IU/week or
30.000 IU/week
3 × 10.000 IU/week or
30.000 IU/week
3 × 20.000 IU/week or
2 × 30.000 IU/week or
1x60.000 IU/week
Epoetin α
3 × 10.000 IU/week or
40.000 IU/week or
30.000 IU/week
3 × 10.000 IU/week or
40.000 IU/week or
30.000 IU/week
3 × 10.000 IU/week or
40.000 IU/week or
30.000 IU/week
3 × 20.000 IU/week or
2 × 30.000 IU/week
Epoetin ζ 3 × 10.000 IU/week
or 40.000 IU/week
3 × 10.000 IU/week or
40.000 IU/week
3 × 10.000 IU/week or
40.000 IU/week
6 × 10.000 IU/week
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quent choice of physicians administered to 2.184 patients
(14.9%) and iron alone was the last one administered to 953
patients (6.5%).
The cost of ESAs treatment classified per Hb level, re-
sponders and non responders on originators and
biosimilar, is presented in Table 4. The cost difference
for responders on originators versus biosimilars is
€336.511 and for non-responders is €1.288.170 respect-
ively. The savings associated with the use of biosimilars
for both patients categories (responders and non-
responders) is estimated at €1.624.681.
Average cost per patient for responders is € 2.887,
using originators (darbepoetin α, epoetin α and epoetin
β) for the 15-week ESAs treatment (6-cycles chemother-
apy) and € 5.019 in the case of non-responders. Average
cost of patients on biosimilar treatment (epoetin α and


















Breast 26.2 4.349 1.139
Lung 47.7 6.667 3.180
Gl-Colon 33 5.062 1.670
Head & Neck 46.1 1.100 507
Gynaecological 42.7 2.026 865
Lymphoma/myeloma 47.4 1.388 658
Leukaemia 53.3 1.512 806
Urogenital 43 5.610 2.412
Other 36.5 9.375 3.422
Total 375.9 37.089 14.660
Sources: 1(Ludwig et al. 2004), 2WHO-Globocan 2008.responders. Responder patients on biosimilars were esti-
mated to have 10.1% lower cost than patients on original
ESAs. In case of non-responders, the cost difference be-
tween originators and biosimilars is even higher reaching
approximately 25.2% favoring also biosimilars.
Discussion
Budget impact estimates reveal that treating newly diag-
nosed chemotherapy-induced anemic patients with origin-
ator ESAs for 6 cycles chemotherapy was estimated at
€10.084.800 compared to €8.460.119 when biosimilar
ESAs were used in both responder and non-responder
patient categories, leading to an overall 19,20% cost reduc-
tion favoring biosimilars. Consequently, budget impact
analysis showed that the administration of biosimilar
ESAs seems to be a cost saving option over originators,
since the savings from the use of biosimilars approximates





















198 170 74 697
553 474 207 1.946
291 249 109 1.022
88 76 33 310
151 129 56 529
114 98 43 403
140 120 52 493
420 359 157 1.476
595 510 222 2.094
2.551 2.184 953 8.972





























Cost of 15 weeks
treatment with
originator ESAs (€)
Cost of 15 weeks
treatment with
originator ESAs (€)
Cost of 15 weeks
treatment with
Biosimilar ESAs (€)
Cost of 15 weeks
treatment with
Biosimilar ESAs (€)
<9 33.5 855 1.233.547 2.144.861 1.120.816 1.713.324 112.731 431.537 544.268
9.0-9.9 27.5 701 1.012.613 1.760.707 920.072 1.406.460 92.541 354.247 446.787
10.0-10.9 24.7 630 909.511 1.581.435 826.392 1.263.257 83.118 318.178 401.296
11.0-11.9 9.5 242 349.812 608.244 317.843 485.868 31.969 122.376 154.345
>12.0 4.8 122 176.747 307.323 160.594 245.491 16.153 61.832 77.985
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savings correspond to the additional treatment of 490 an-
aemic patients.
However, there are certain limitations in the current
analysis that should be discussed. First, given the limited
experience in the use of biosimilars, it is rather difficult
to compare and generalize our findings with inter-
national literature. The only study with comparable re-
sults is that of Aapro et al. [5] which compared the cost
of chemotherapy-induced anaemia among originator
epoetin α, epoetin β and darbepoetin α and biosimilar
epoetin α at the level of a single patient using various
dosing scenarios. Although the above study compared a
single biosimilar agent with the rest originators category
whilst in our analysis all biosimilar treatments were used
and compared with the whole originators category, still
both studies revealed saving by the use of biosimilars.
Second, given that substitution on ESAs is not
recommended by the European Agencies for medicines,
the current research hypothesis is conservative, since it
is based only on incidence rates without taking into con-
sideration cancer patients already on treatment with an
originator ESA. Additionally, the rates of cancer anaemic
patients on treatment were based on ECAS study
performed in 2004, which might not reflect potential
changes in the current epidemiological rates. Also the
assumption of 50% response rate of the cancer anaemia
patients was necessary due to lack of respective inter-
national data in order to keep a balance between the
comparable categories. Finally, the fact that the present
study focuses on the ESAs consumption and does not
take into consideration neither the alternative treatment
option of transfusions nor the supplementary treatment
of ESAs with iron constitutes another limitation.
It is believed that although sound national and inter-
national evidence have been used for the estimation of
epidemiological chemotherapy-induced anaemia and dis-
ease management data, still further research on patient
reported outcomes deriving from empirical evidence, is
needed. In addition, the authors would like to point out
that an evaluation of the efficacy/effectiveness and safety
of ESAs for their intended use and their approved thera-
peutic indications were not within the aims of the study.
The current budget-impact analysis was based on the
use of ESAs in Greece, their approved therapeutic indi-
cations and posology regimens, among originators and
biosimilars.
Despite the above research limitations, it should be
mentioned that the conduction of budget impact analysis
of originators versus biosimilars seems to be important
both at the micro and macro-economic level, especially
for reimbursement decisions making and health resources
re-allocation purposes. However, comparing among alter-
native therapeutic options for managing chemotherapy-induced anaemia, more complex analysis is needed. The
conduction of cost-effectiveness or cost-utility analyses
focusing on alternative management strategies for
chemotherapy-induced anaemia might result in more
comparable treatment costs and clinical outcomes.
Economic evaluation studies combine budgets’ savings
with clinical evidence that could lead in the expansion
of patients’ access to ESAs, the avoidance of blood
wastes as well as to the improvement of patients’ quality
of life.
Conclusion
The administration of biosimilar ESAs to newly diag-
nosed chemotherapy-induced anemic patients seems to
be a cost saving option over originators, although further
research on patient reported outcomes and empirical
evidence is needed. Under the economic recession that
Greece is experiencing, health care decision making
should rely on evidence based treatments in order to
achieve social funds’ sustainability.
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